Listen
BOTOX
-
Opinions on drugs -
Posted on
Dec 15 2009
- Updated on
Jan 26 2010
Reason for request
Inclusion on the list of medicines approved for use by hospitals and various public services in the extension of the therapeutic indication: In children over 2 years of age “Local symptomatic treatment of spasticity (muscle hyperactivity) of the upper and/or lower limbs”.
-
Clinical Benefit
| Substantial |
The actual benefit of these proprietary products in this new indication is substantial. |
Clinical Added Value
| minor |
BOTOX (botulinum toxin type A) products provide a minor improvement in actual benefit (IAB IV) in terms of efficacy in the treatment of spasticity (muscle hyperactivity) of the upper and/or lower limbs in children aged 2 years and over. |
Documents
English version
Contact Us
Évaluation des médicaments
